Structure Therapeutics Inc..
GPCR.US | Research and experimental development on natural sciences and engineering
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapeutics targeting G protein-coupled receptors (GPCRs) for the treatment of a variety of diseases. The company utilizes its proprietary structure-based drug discovery platfo...Show More
Better Health for All
20
Structure Therapeutics Inc. is focused on developing novel oral small molecule therapeutics for metabolic diseases, primarily obesity and diabetes.
1
Its lead molecule, ACCG-2671, an oral small molecule amylin receptor agonist for obesity, is designed to reduce appetite, increase satiety, and improve energy expenditure.
2
Another molecule, aleniglipron, a once-daily oral small molecule GLP-1 receptor agonist, showed significant positive Phase 2 clinical data, including placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with the 120 mg dose and up to 15.3% (35.5 lbs) with the 240 mg dose at 36 weeks.
3
It also demonstrated clinically meaningful improvements in systolic blood pressure (-6.4 to -7.5 mmHg) and HbA1c (-0.28% to -0.37%).
4
The company's entire business is devoted to health improvement in this area. The company is developing oral small molecule compounds to surpass scalability limitations of traditional biologic and peptide therapies, aiming to be accessible to more people globally.
5
Studies for aleniglipron enrolled adult participants with obesity (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) with at least one weight-related comorbidity.
6
The company utilizes a next-generation structure-based drug discovery platform and has established a robust GPCR-targeted pipeline, indicating significant investment in health innovation.
7
For aleniglipron, the most common adverse events (AEs) were gastrointestinal-related, with an AE-related treatment discontinuation rate ranging from 7.7% to 13.3% across active arms in the Phase 2b ACCESS study.
8
The company acknowledges risks and uncertainties in its forward-looking statements related to clinical trial results and regulatory approvals.
9
Clinical studies for aleniglipron were randomized, double-blind, placebo-controlled.
10
Fair Money & Economic Opportunity
0
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on drug discovery and development, not a financial institution.
1
The company does not offer lending, insurance, or deposit services to consumers, nor does it manage customer financial data or provide debt products.
2
Therefore, all KPIs related to financial services, such as underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives, data accessibility, fair lending compliance, wealth building outcomes, profit reinvestment in community finance, financial literacy initiatives, debt burden ratio, geographic inclusion of financial services, and product simplicity of financial offerings, are not applicable to its core business model.
3
Fair Pay & Worker Respect
0
No specific, concrete data points were found in the provided articles to assess Structure Therapeutics Inc. against the Fair Pay & Worker Respect KPIs. The articles primarily focus on financial results, R&D expenses, and clinical trial updates. While Glassdoor reviews provide qualitative ratings for aspects like CEO approval (51%), culture & values (3.1), and compensation & benefits (3.1), these do not provide the quantitative metrics required by the rubric for KPIs such as living wage coverage, CEO-median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score (as a single index), turnover rate, labor violation incidents, insecure contract share, or health insurance coverage.
1
Fair Trade & Ethical Sourcing
0
No relevant evidence was found in the provided articles to assess GPCR.US against the 'Fair Trade & Ethical Sourcing' value. The single article provided failed to extract data, rendering it unusable for scoring.
1
Honest & Fair Business
0
No evidence available to assess Structure Therapeutics Inc. on Honest & Fair Business.
Kind to Animals
-40
The company's collaboration agreement references the United States Animal Welfare Act and Good Laboratory Practices for toxicology studies, indicating adherence to legal mandates.
1
Its partner, Schrödinger, provides computational modeling and design support, including virtual screens, which are alternative testing methods.
2
However, the extent to which these alternative methods are employed by Structure Therapeutics Inc. for product safety and efficacy is not specified.
No War, No Weapons
0
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral therapeutics for diseases such as obesity and diabetes.
1
Its core business is research and development of pharmaceutical products.
2
The provided articles, which include a financial report, do not contain any information regarding the company's involvement in arms manufacturing, military contracts, dual-use technologies, sales to embargoed regimes, or any peacebuilding initiatives.
3
There is no evidence of defense-related assets, lobbying, procurement, or operations in conflict-affected areas.
4
Therefore, all KPIs related to military, defense, or conflict activities are scored as N/A, indicating no applicable business activities in these areas.
Planet-Friendly Business
0
No specific, concrete data points related to environmental performance, emissions, renewable energy, water usage, waste, certifications, or climate-related policies for Structure Therapeutics Inc. were found in the provided articles.
1
The articles explicitly state that sustainability data is not available or could not be extracted.
2
Respect for Cultures & Communities
0
No evidence available to assess Structure Therapeutics Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
0
The company has no specific data breach incidents or severity levels reported.
1
There are also no specific incidents of unauthorized data use reported.
2
The company mentions compliance with SOX, indicating basic adherence to relevant regulations.
3
Zero Waste & Sustainable Products
0
No specific, concrete data points or initiatives related to waste management, product recyclability, packaging sustainability, or other zero waste and sustainable product metrics for GPCR.US were found in the provided articles.
1
The articles either discuss general industry trends, market forecasts, or explicitly state that no sustainability data is available for the company.
2